Facial plastic surgery & aesthetic medicine · 2026
Intravenous Tranexamic Acid in Rhinoplasty: A Randomized Controlled Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Longino Elizabeth S, Desisto Nicole G, Adegboye Feyi, Rebula Emily, Chowdhury Naweed I, Patel Priyesh N, Stephan Scott J, Yang Shiayin F
Аннотация
BACKGROUND: Existing data on tranexamic acid (TXA) in rhinoplasty are mixed.
OBJECTIVE: Compare blood loss, edema, and bruising in patients undergoing septorhinoplasty with or without intravenous (IV) TXA, measured by estimated blood loss and photograph review of edema/ecchymosis.
DESIGN: Randomized controlled trial (NCT05774717).
METHODS: Patients undergoing open septorhinoplasty were eligible. Participants were randomized to receive 1 g IV TXA preoperatively or routine medications only. Intraoperative bleeding was measured using the Boezaart scale and sponge saturation. Patients rated periorbital edema/ecchymosis at 1 week. Photos were reviewed by a facial plastic surgeon to grade edema/ecchymosis.
RESULTS: There were 139 participants: 73 (53%) female, mean age of 42 ± 15 years, and 13% revision procedures. Sixty-nine (50%) received TXA. Boezaart scores were 2.25 and 2.41 (p = 0.3), and sponge scores were 0.76 and 0.84 (p = 0.4) in the TXA and control groups, respectively. Postoperative edema/ecchymosis were 1.15/1.19 out of 4 in the TXA group, and 0.97/1.05 in the control group. Surgeon-graded edema/ecchymosis were 1.78/1.76 (TXA) and 1.82/1.86 (control). There was no difference in epistaxis, pain, or appearance satisfaction.
CONCLUSIONS: In this study, there was no difference in bleeding, edema, ecchymosis, or postoperative experience associated with TXA.
OBJECTIVE: Compare blood loss, edema, and bruising in patients undergoing septorhinoplasty with or without intravenous (IV) TXA, measured by estimated blood loss and photograph review of edema/ecchymosis.
DESIGN: Randomized controlled trial (NCT05774717).
METHODS: Patients undergoing open septorhinoplasty were eligible. Participants were randomized to receive 1 g IV TXA preoperatively or routine medications only. Intraoperative bleeding was measured using the Boezaart scale and sponge saturation. Patients rated periorbital edema/ecchymosis at 1 week. Photos were reviewed by a facial plastic surgeon to grade edema/ecchymosis.
RESULTS: There were 139 participants: 73 (53%) female, mean age of 42 ± 15 years, and 13% revision procedures. Sixty-nine (50%) received TXA. Boezaart scores were 2.25 and 2.41 (p = 0.3), and sponge scores were 0.76 and 0.84 (p = 0.4) in the TXA and control groups, respectively. Postoperative edema/ecchymosis were 1.15/1.19 out of 4 in the TXA group, and 0.97/1.05 in the control group. Surgeon-graded edema/ecchymosis were 1.78/1.76 (TXA) and 1.82/1.86 (control). There was no difference in epistaxis, pain, or appearance satisfaction.
CONCLUSIONS: In this study, there was no difference in bleeding, edema, ecchymosis, or postoperative experience associated with TXA.